Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

202159 citationsJournal Articlegold Open Access

Authors

Hideki Iwamoto · Kurume University

Shigeo Shimose · Kurume University

Yu Noda · Kurume University

Tomotake Shirono · Kurume University

Takashi Niizeki · Kurume University

Masahito Nakano · Kurume University

Shusuke Okamura · Kurume University

Abstract

The study demonstrated that atezolizumab plus bevacizumab was effective and safe for patients with HCC even in the real-world setting including patients with a previous MTA history or other than ALBI grade 1.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Hepatitis B Virus Studies Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancers

Volume 13, Issue 11, pp. 2786-2786

DOI: 10.3390/cancers13112786

Field-Weighted Citation Impact: 6.39